- Home
- MYGN vs TSSI Comparison
MYGN vs TSSI Comparison
Compare MYGN & TSSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- TSSI
- Stock Information
- Founded
- MYGN 1991
- TSSI 2004
- Country
- MYGN United States
- TSSI United States
- Employees
- MYGN N/A
- TSSI N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TSSI Professional Services
- Sector
- MYGN Health Care
- TSSI Consumer Discretionary
- Exchange
- MYGN Nasdaq
- TSSI Nasdaq
- Market Cap
- MYGN 642.0M
- TSSI 677.8M
- IPO Year
- MYGN 1995
- TSSI N/A
- Fundamental
- Price
- MYGN $7.88
- TSSI $19.60
- Analyst Decision
- MYGN Hold
- TSSI
- Analyst Count
- MYGN 13
- TSSI 0
- Target Price
- MYGN $13.50
- TSSI N/A
- AVG Volume (30 Days)
- MYGN 1.5M
- TSSI 3.1M
- Earning Date
- MYGN 11-06-2025
- TSSI 11-21-2025
- Dividend Yield
- MYGN N/A
- TSSI N/A
- EPS Growth
- MYGN N/A
- TSSI 311.74
- EPS
- MYGN N/A
- TSSI 0.34
- Revenue
- MYGN $832,900,000.00
- TSSI $263,021,000.00
- Revenue This Year
- MYGN $0.17
- TSSI N/A
- Revenue Next Year
- MYGN $6.19
- TSSI N/A
- P/E Ratio
- MYGN N/A
- TSSI $52.35
- Revenue Growth
- MYGN 3.83
- TSSI 328.79
- 52 Week Low
- MYGN $3.76
- TSSI $5.04
- 52 Week High
- MYGN $26.60
- TSSI $31.94
- Technical
- Relative Strength Index (RSI)
- MYGN 57.10
- TSSI 60.97
- Support Level
- MYGN $7.04
- TSSI $17.71
- Resistance Level
- MYGN $8.25
- TSSI $20.94
- Average True Range (ATR)
- MYGN 0.38
- TSSI 1.67
- MACD
- MYGN -0.06
- TSSI 0.36
- Stochastic Oscillator
- MYGN 54.77
- TSSI 79.03
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About TSSI TSS Inc. Common Stock
TSS Inc provides various services for planning, design, development, and maintenance of mission-critical facilities and information infrastructure, as well as integration services. Its services consist of technology consulting, design and engineering, project management, systems integration, systems installation, facilities management, and IT procurement services. The activities are organized into two segments: Procurement, Systems Integration, and Facilities Management. It generates the majority of its revenue from the Procurement segment.